Table 2.
Statistical analysis of quality of life; subscales of the Multiple Sclerosis Quality of Life-54 questionnaire
| Subscales of MSQoL questionnaire | Placebo treatment (n = 14) | um-PEA treatment (n = 15) | p-Value | ||||
|---|---|---|---|---|---|---|---|
| 1 month | 6 months | 12 months | 1 month | 6 months | 12 months | ||
| Physical health | 75.8 ± 20.8 | 71.3 ± 21.4 | 56.0 ± 15.6 | 74.6 ± 22.8 | 72.7 ± 19.5 | 62.9 ± 17.0 | |
| Role limitations due to physical problems | 48.1 ± 45.0 | 45.8 ± 38.0 | 57.0 ± 42.4 | 56.8 ± 38.2 | 50.0 ± 33.0 | 37.1 ± 39.5 | |
| Role limitation due to emotional problems | 53.8 ± 44.2 | 71.0 ± 34.7 | 63.4 ± 40.0 | 68.1 ± 34.8 | 50.4 ± 37.5 | 36.7 ± 34.9 | |
| Pain | 63.7 ± 23.8 | 62.5 ± 25.3 | 61.6 ± 29.6 | 73.3 ± 20.1 | 66.3 ± 17.0 | 41.9 ± 27.0 | |
| Emotional well-being | 55.7 ± 23.0 | 59.0 ± 20.8 | 52.0 ± 13.2 | 64.6 ± 4.2 | 57.2 ± 19.9 | 37.1 ± 21.4 | |
| Energy | 51.9 ± 16.2 | 51.9 ± 13.8 | 52.0 ± 16.2 | 50.9 ± 18.7 | 47.0 ± 11.7 | 45.7 ± 15.1 | |
| Health perceptions | 46.9 ± 8.1 | 44.8 ± 11.1 | 43.0 ± 8.2 | 43.9 ± 13.6 | 53.4 ± 12.5 | 40.0 ± 18.9 | |
| Cognitive function | 74.2 ± 19.7 | 63.7 ± 16.4 | 52.0 ± 21.5 | 71.4 ± 21.9 | 50.8 ± 26.7 | 51.4 ± 22.7 | 0.0065 |
| Social function | 77.4 ± 14.7 | 77.0 ± 17.3 | 57.6 ± 24.9 | 69.5 ± 15.7 | 72.5 ± 17.9 | 58.9 ± 20.0 | |
| Health distress | 51.6 ± 10.0 | 51.8 ± 10.7 | 49.2 ± 13.0 | 46.7 ± 0.0 | 41.3 ± 12.4 | 42.8 ± 15.3 | |
| Sexual function | 90.8 ± 23.1 | 87.8 ± 24.7 | 77.2 ± 25.6 | 83.0 ± 5.8 | 92.3 ± 12.7 | 65.8 ± 28.2 | |
| Sexual satisfaction | 65.8 ± 26.3 | 75.0 ± 28.0 | 74.0 ± 3.2 | 74.6 ± 25.4 | 75.0 ± 23.2 | 60.7 ± 19.0 | |
| Change in health | 41.9 ± 25.3 | 58.3 ± 28.0 | 49.5 ± 35.0 | 49.6 ± 16.9 | 62.5 ± 18.9 | 31.5 ± 17.5 | 0.0396 |
| Overall quality of life | 50.8 ± 20.4 | 58.5 ± 18.3 | 46.7 ± 17.4 | 56.2 ± 16.6 | 46.3 ± 8.3 | 41.8 ± 14.2 | |
Results are reported as mean ± SD
um-PEA = ultramicronized palmitoylethanolamide